Dave Ricks, Eli Lilly
Eli Lilly buys a Roche discard in $1.1B Dermira buyout. Can they go toe-to-toe with the heavyweight challenger Dupixent?
Eli Lilly thinks it has found a better way to tackle the atopic dermatitis market now being dominated by Dupixent.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
